Wealthfront Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.37M | Sell |
7,006
-1,338
| -16% | -$911K | 0.01% | 460 |
|
|
2026
Q1 | $6.45M | Buy |
8,344
+202
| +2% | +$155K | 0.01% | 365 |
|
|
2025
Q4 | $6.28M | Buy |
8,142
+2,202
| +37% | +$1.5M | 0.01% | 348 |
|
|
2025
Q3 | $3.34M | Buy |
5,940
+1,325
| +29% | +$749K | 0.01% | 475 |
|
|
2025
Q2 | $2.42M | Sell |
4,615
-1,560
| -25% | -$871K | 0.01% | 530 |
|
|
2025
Q1 | $3.92M | Sell |
6,175
-1,173
| -16% | -$807K | 0.01% | 403 |
|
|
2024
Q4 | $5.23M | Sell |
7,348
-2,141
| -23% | -$1.8M | 0.02% | 320 |
|
|
2024
Q3 | $9.98M | Sell |
9,489
-97
| -1% | -$108K | 0.03% | 165 |
|
|
2024
Q2 | $10.1M | Sell |
9,586
-154
| -2% | -$149K | 0.03% | 152 |
|
|
2024
Q1 | $9.37M | Buy |
9,740
+129
| +1% | +$123K | 0.03% | 151 |
|
|
2023
Q4 | $8.44M | Buy |
9,611
+145
| +2% | +$119K | 0.03% | 151 |
|
|
2023
Q3 | $7.79M | Sell |
9,466
-1,179
| -11% | -$927K | 0.03% | 153 |
|
|
2023
Q2 | $7.65M | Sell |
10,645
-5,943
| -36% | -$4.58M | 0.03% | 157 |
|
|
2023
Q1 | $13.6M | Buy |
16,588
+6,294
| +61% | +$4.75M | 0.06% | 87 |
|
|
2022
Q4 | $7.43M | Sell |
10,294
-75
| -0.7% | -$55.3K | 0.04% | 147 |
|
|
2022
Q3 | $7.14M | Buy |
10,369
+1,749
| +20% | +$1.1M | 0.04% | 127 |
|
|
2022
Q2 | $5.1M | Buy |
8,620
+4,881
| +131% | +$3.17M | 0.03% | 181 |
|
|
2022
Q1 | $2.61M | Buy |
3,739
+40
| +1% | +$25.3K | 0.01% | 339 |
|
|
2021
Q4 | $2.34M | Buy |
3,699
+130
| +4% | +$79.9K | 0.01% | 348 |
|
|
2021
Q3 | $2.16M | Buy |
3,569
+76
| +2% | +$47.2K | 0.01% | 331 |
|
|
2021
Q2 | $1.95M | Sell |
3,493
-2,990
| -46% | -$1.51M | 0.01% | 311 |
|
|
2021
Q1 | $3.07M | Sell |
6,483
-1,221
| -16% | -$594K | 0.02% | 178 |
|
|
2020
Q4 | $3.72M | Buy |
7,704
+3,301
| +75% | +$1.78M | 0.02% | 125 |
|
|
2020
Q3 | $2.46M | Sell |
4,403
-678
| -13% | -$411K | 0.02% | 146 |
|
|
2020
Q2 | $3.17M | Buy |
5,081
+4,205
| +480% | +$2.39M | 0.02% | 110 |
|
|
2020
Q1 | $428K | Buy |
876
+165
| +23% | +$68.1K | ﹤0.01% | 363 |
|
|
2019
Q4 | $267K | Buy |
+711
| New | +$239K | ﹤0.01% | 458 |
|
|
2019
Q3 | – | Sell |
-1,324
| Closed | -$414K | – | 487 |
|
|
2019
Q2 | $414K | Sell |
1,324
-166
| -11% | -$55.3K | ﹤0.01% | 406 |
|
|
2019
Q1 | $612K | Buy |
1,490
+439
| +42% | +$181K | 0.01% | 335 |
|
|
2018
Q4 | $393K | Buy |
+1,051
| New | +$385K | ﹤0.01% | 368 |
|
Other funds holding REGN
Wealthfront Advisers's REGN Position: Q2 2026 in Review
Wealthfront Advisers reduced its Regeneron Pharmaceuticals (REGN) stake by 16% in Q2 2026, selling an estimated $911K and leaving 7,006 shares worth $4.37M. The position accounts for 0.01% of the portfolio, ranked #460.
Wealthfront Advisers first reported a position in REGN in Q4 2018 and has held it in 30 quarters since. The position peaked at $13.6M in Q1 2023. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Wealthfront Advisers held 7,006 shares of Regeneron Pharmaceuticals worth $4.37M as of Q2 2026.
- Wealthfront Advisers sold 1,338 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $911K.
- Regeneron Pharmaceuticals made up 0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #460 holding.
- Wealthfront Advisers first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 30 quarters since.
- Wealthfront Advisers's Regeneron Pharmaceuticals position peaked at $13.6M in Q1 2023.
- 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.